Loading company…
Shanghai Junsai Biotechnology develops tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors.
Based in Shanghai, China and established in 2019, Shanghai Junsai Biotechnology focuses on tumor infiltrating lymphocyte (TIL) therapies for solid tumors. It develops first-in-class and best-in-class cell-based drugs for recurrent refractory malignancies. The company has completed four rounds of funding as of 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in